We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sareum Holdings Plc | LSE:SAR | London | Ordinary Share | GB00BMC3RJ87 | ORD GBP 0.0125 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 27.00 | 76,801 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 26.00 | 28.00 | 27.00 | 27.00 | 27.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | -3.19M | -0.0296 | -9.12 | 29.15M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:27:49 | O | 7,659 | 26.55 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/12/2024 | 16:07 | UK RNS | Sareum Holdings PLC Results of AGM |
| 19/12/2024 | 07:00 | UK RNS | Sareum Holdings PLC AGM Statement |
| 18/12/2024 | 07:00 | UK RNS | Sareum Holdings PLC Appointment of Joint Broker |
| 17/12/2024 | 09:14 | UK RNS | Sareum Holdings PLC Holding(s) in Company |
| 16/12/2024 | 07:00 | UK RNS | Sareum Holdings PLC Award of Share Options |
| 27/11/2024 | 09:38 | UK RNS | Sareum Holdings PLC Notice of AGM, Annual Report and Accounts |
| 29/10/2024 | 14:27 | ALNC |  Sareum annual loss widens as remains focused on autoimmune diseases |
| 29/10/2024 | 07:00 | UK RNS | Sareum Holdings PLC Final Results for the Year Ended 30 June 2024 |
| 23/10/2024 | 06:00 | UK RNS | Sareum Holdings PLC Notice of Final Results and Investor Presentation |
| 21/10/2024 | 17:21 | ALNC | IN BRIEF: Sareum raises further GBP1.0 million via subscription |
Sareum (SAR) Share Charts1 Year Sareum Chart |
|
1 Month Sareum Chart |
Intraday Sareum Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 20/12/2024 | 12:10 | Sareum 2015 | 18,376 |
| 03/10/2024 | 11:00 | Share Price will crash by 99%, ramped by criminal Siko. | 87 |
| 09/9/2024 | 21:02 | share price will SURGE through the Ј1 barrier again | 28 |
| 09/8/2024 | 13:35 | SAR - Sareum Holdings drug discovery | 372 |
| 09/8/2024 | 10:21 | SAR 2013 , SHORT THE ARSE OUT OF IT THREAD | 327 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-12-20 16:27:51 | 26.55 | 7,659 | 2,033.46 | O |
| 2024-12-20 16:14:45 | 28.00 | 95 | 26.60 | O |
| 2024-12-20 15:09:12 | 26.55 | 1,500 | 398.25 | O |
| 2024-12-20 14:37:55 | 27.35 | 19,034 | 5,205.80 | O |
| 2024-12-20 14:31:32 | 26.55 | 11,054 | 2,934.84 | O |
| Top Posts |
|---|
Posted at 21/12/2024 08:20 by Sareum Daily Update Sareum Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SAR. The last closing price for Sareum was 27p.Sareum currently has 107,950,000 shares in issue. The market capitalisation of Sareum is £29,146,500. Sareum has a price to earnings ratio (PE ratio) of -9.12. This morning SAR shares opened at 27p |
Posted at 20/11/2024 20:50 by criticalthinker1 Has the handbrake been put on Sareum...you tell me...7 Oct 2021 10:42 RNS Number : 3573O Sareum Holdings PLC 07 October 2021 SAREUM HOLDINGS PLC ("Sareum" or "the Company") US Patent Granted for Sareum's SDC-1802 TYK2/JAK1 Inhibitor Cambridge, UK, 7 October 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces that, further to its announcement of 30 July 2021, the United States Patent and Trademark Office has now formally approved its patent in respect of an invention associated with Sareum's proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the "SDC-1802 Programme"). The patent (US 11,154,539) will grant on 26 October 2021 and will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase. This programme is in preclinical development. Sareum's CSO, Dr John Reader, commented: "We are pleased to confirm the grant of this US patent for SDC-1802, adding another layer of protection around this promising candidate in key territories. Our SDC-1802 programme is in preclinical development currently and we are designing the translational studies needed to define the optimal cancer application prior to completing toxicology and manufacturing studies. We look forward to providing further updates on progress as we achieve key milestones." |
Posted at 29/10/2024 15:47 by wolfofwallstreets And lse take the little breadcrumbs and the cycle starts over..Partner companies...opportun Then nothing for months... Then 737 will get handed back... Share price will collapse.. Then they will release some news... Share price recovers... More placings... Then the next annual meeting.. |
Posted at 03/10/2024 18:31 by criticalthinker1 Henry. Its a shame one has to respond to disrupters with the detail you have given. But well done. Personally I don't suffer fools gladly. Not specifically re your response but I can definitely agree with your response re attaining information from posters.A neighbour of mine who moved away a couple years ago is an individual who is very quiet but VERY clever. He sold his company (albeit employed again to run his ipr) that is being used by the US government to attain information from hard drives that what individuals think is deleted...isn't. I can put him in contact with your own endeavours if he is accepting of the idea. But I might add he is a grey man. Moving on.... Interesting posts re our potential worth. I would like to remind individuals of this re our 1801 being very successful in ARDS re 'covid' albeit being a coronavirus....so remember 1801 went in vivo in 2021!! This is an extract of the RNS. London South East Rainbow Rare Earths discuss progress and continued flowsheet optimisation at Phalaborwa Project. Watch the interview here. Less Ads, More Data, More Tools Register for FREE Share PricesSareum Share PriceSareum Share Regulatory NewsCovid-19 Research Project Results Pin to quick picksSareum Regulatory News (SAR) SAR Share Price SAR Share Price SAR Share News SAR Share News SAR Share Chat SAR Share Chat 46 SAR Share Trades SAR Share Trades 15 SAR Live RNS SAR Live RNS Sponsored Content Sareum Information Buy SAR Shares Buy SAR Shares Add SAR to Watchlist Add SAR to Watchlist Add SAR to Alert Add SAR to Alert SAR Live PriceLast checked at 19:07:41 Share Price Information for Sareum (SAR) London Stock Exchange Share Price is delayed by 15 minutes Get Live Data Share Price: 27.50 Bid: 27.00 Ask: 28.00 Change: 0.50 (1.85%) Spread: 1.00 (3.704%)Open: 27.00High: 27.50Low: 27.00Prev. Close: 27.00 Sponsored Content Covid-19 Research Project Results 1 Jul 2021 07:00 RNS Number : 7338D Sareum Holdings PLC 01 July 2021 Sareum Holdings PLC ("Sareum" or the "Company") Completed Covid-19 Research Project Delivers Encouraging Results Cambridge, UK, 1 July 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce encouraging top-line results from its UKRI grant funded Covid-19 research project. The aim of this research project was to investigate the effects of SDC-1801, the Company's proprietary TYK2/JAK1 inhibitor, on cytokine signalling after SARS-CoV-2 infection. It was also designed to confirm whether an over-active inflammatory response (known as a 'cytokine storm') via the Interferon Type 1 pathway can be blocked in this disease by SDC-1801. The project has completed on schedule, with the final results confirming the initial encouraging results as noted in the Company's Interim Results, published on 23 April 2021. The results of the project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor. Subsequent completed in-vivo studies support the initial cellular results and indicate: · Strong evidence that expression of Type 1 interferons (IFNa and IFNb) is reduced by SDC-1801 treatment in a dose-responsive manner; and that · Viral loads did not increase after SDC-1801 administration, a potential concern when anti-inflammatory agents are used to dampen down an over-active immune response A secondary objective, the investigation into whether treatment with SDC-1801 in disease models could protect against bacterial pneumonia following SARS-CoV-2 infection was inconclusive, due to technical shortcomings in the disease model. And then the shenanigans became apparent. I've been a continuous supporter of Sareum and made my points clear about decisions that were not correct..but I firmly feel we have been under attack. I mean a buy is quickly followed by a sell and then relatively noteable buys are imo supported by sells that cover them...as if a company is drip feeding a client.. All best Steadydanny So much more to say but will hold back. |
Posted at 11/9/2024 18:43 by criticalthinker1 Interesting talk on lse!...but still seem imo a bit lax in their knowledge..not all but just saying that some seem to hold court there but miss noteable facts...noteabley this re 1801Cambridge, UK, 1 July 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce encouraging top-line results from its UKRI grant funded Covid-19 research project. The aim of this research project was to investigate the effects of SDC-1801, the Company's proprietary TYK2/JAK1 inhibitor, on cytokine signalling after SARS-CoV-2 infection. It was also designed to confirm whether an over-active inflammatory response (known as a 'cytokine storm') via the Interferon Type 1 pathway can be blocked in this disease by SDC-1801. The project has completed on schedule, with the final results confirming the initial encouraging results as noted in the Company's Interim Results, published on 23 April 2021. The results of the project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor. Subsequent completed in-vivo studies support the initial cellular results and indicate: · Strong evidence that expression of Type 1 interferons (IFNa and IFNb) is reduced by SDC-1801 treatment in a dose-responsive manner; and that · Viral loads did not increase after SDC-1801 administration, a potential concern when anti-inflammatory agents are used to dampen down an over-active immune response A secondary objective, the investigation into whether treatment with SDC-1801 in disease models could protect against bacterial pneumonia following SARS-CoV-2 infection was inconclusive, due to technical shortcomings in the disease model. So sareum holders don't forget that our 1801 was in vivo. So imo that's clinical work undertaken. Actually in vivo...not JUST vitro...I am so perplexed that this point is not discussed on lse. Maybe it might occur as it seems to me some of the lse posters are talkative albeit lacking in the position our company is...but talkative non the less...yes potnak I don't trust you as far as I could throw you...just my opinion. All best Steadydanny |
Posted at 03/9/2024 21:19 by criticalthinker1 Its interesting reading the thoughts on lse but some are forgetting what is still part of the past....which one should always keep an eye on when predicting the future.Namely we need clarification from the board as to why the MHRA didnt let us go forward for trials...which was put together by world leading individuals as per the rns...yet we effectively got screwed..and now the government are pushing homegrown drug trials...you literally couldn't make up the shambles our country is! Also a pretty significant thing to remember is back in 2022 the board believed that the share price at the time of shares available was worth a minimum of £3.50 in respect to the individuals who introduced the subscribers as they are offered 29m shares ar 5p (£2.50 £1.5m ish) when the share price reaches 7p (£3.50) for a minimum of 5 consecutive days!!!! Note this lapses 2026...so the individuals saying £3....might want to rethink... Not to mention the other warrants that are an option at various share prices!! And just check out the timings of the above and the chronology of the share price!!!!!! And albeit the RF FU..we are now a clinical company and have extended our patents...be that approved and an intimation of Allowance...and look where we are irrespective of the dilution...we are still nowhere where we should be...especially if you take the oldies motto with listed companies Buy before news expectation and sell where and when you deem the news to be valued. So anyone literally saying everything is priced in is talking absolute bollards. We have been a target of nefarious means since 2022! No way I'm letting my shares go cheap! |
Posted at 06/8/2024 17:12 by peaceandlove This company is unprofessional IMHO. Over a year since 1801 started its clinical trial and still no news on where they go next? The way Sareum treat shareholders is staggering. Absolutely no communication, and no licence or takeover deals on the horizon. I reckon by early September the share price will be below 20p, and Sadoldgit, Abery, Laz will still be banging on that Sareum is a multi £billion pound company. It's truly astonishing how people think the current MCAP can go from £28million to £billions in a short space of time. I actually believe a Placing is on the cards and the share price will eventually drop below 10p. As I've told everyone many times, this could go on for years and years. Unbelievable! £1 share, you're having a laugh 🤭 |
Posted at 08/7/2024 13:00 by peaceandlove It's called sarcasm Boo 👻 Hoo. 🤦🏻 BTW, why do you always use foul language?What you and I say and indeed anyone else for that matter doesn't affect the share price The share price will continue to fall until Sareum announce how they're going to fund the continuation of their clinical trial. Don't you have any opinions or facts about this company? Very odd! I've given my thoughts on sareum. The whole idea of this board is to share information and give opinions, which means both sides to the argument. |
Posted at 02/7/2024 08:17 by peaceandlove At last a honest post on LSE. Well done 👏 👏👏&#Reality10 Posts: 59 Price: 39.00 No Opinion RE: Share price.Today 09:12 If you listen to SOG, Laz, carter, bailiff annd countless others etc. they are super rampers you will get trapped in this share. What has happened here is, Sareums data package is late again. Yes it’s very very positive so far, but we have to wait another 3 months until potentially end of Q3 for the full data read out, so it’s late as the market expected end of Q2. SOG nothing personal, your knowledge is far above anyone’s here when it comes to the science, im the first to admit it, I even enjoy reading your postings, but your constantly criticising people with a more realistic view of what is going on here with regards to share price expectations. Laz, carter and Baliff are nothing more than cheer leaders that offer nothing but hopium. So until this data comes out and unless some news on say 737 comes out which is a possibility, this share price will slide as we will witness in the coming days and weeks. Even with the data readout, funding has to be sorted out so again don’t get caught out by all the ramping. Long term money will be made here but all you rampers stop the ramping you look foolish. Did I sell a large chunk of my money yesterday, yes I did, but I have a large holding still |
Posted at 04/6/2024 19:29 by criticalthinker1 I think Emma is in the queue Wolfie. It's tiring looking in on here and seeing the seriously unbalanced and deranged responses you give.The clue was for all to see last year in a RNS posted by Sareum (below) and since that RNS things have seen a great leap in the progression of 1801 and 1802 will follow and 737 ticking along despite your lies to acknowledge the proof I had it was still progressing. RNS Sareum announces two new granted patents, including first patent specifically for SDC-1801 Cambridge, UK, 26 June 2023 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces that the first patent specifically relating to SDC-1801, its lead TYK2/JAK1 kinase inhibitor, has been granted in China. Further, a patent has been formally granted for SDC-1802 and several analogues in the United States, extending the scope of protection beyond immuno-oncology. Dr John Reader, Sareum's Chief Scientific Officer, commented: "We're delighted to have the first patent granted for SDC-1801, our lead development programme which recently advanced into a Phase 1a clinical trial in Australia. We look forward to being able to strengthen our intellectual property around this asset in other territories in due course." "Separately, we are really pleased to have extended the scope of patent protection for SDC-1802 in the US. Although oncology remains the primary focus of this asset, this bulwarks our intellectual property position and gives us optionality to explore opportunities in other therapeutic areas." SDC-1801 is a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune dermatological condition affecting more than 60 million adults worldwide, with a market size for potential treatments estimated to be worth more than US$30 billion. Sareum recently announced that it has begun dosing healthy subjects in a Phase 1a clinical trial for SDC-1801, in Australia. The China National Intellectual Property Administration (CNIPA) has officially issued patent number CN113056456B, safeguarding SDC-1801 and medical applications of it in treating inflammatory or immune disorders. This is the first patent grant issued to Sareum for SDC-1801 in any territory. Patent applications in Europe (EP3864009), the US (US2021387981) and other territories are still under review. SDC-1802 is a TYK2/JAK1 inhibitor being developed for cancer immunotherapy. Sareum continues to work on the translational studies needed to support the development of SDC-1802, defining the optimal cancer application prior to completing toxicology and manufacturing studies. The United States Patent and Trademark Office (USPTO) has formally granted patent number US 11,673,870 B2 specifically covering the treatment of autoimmune disorders with SDC-1802 and several analogues. While Sareum has previously secured international patents providing comprehensive protection for the compound SDC-1802, this patent extends its scope in the US beyond immuno-oncology. Just read that and see where we are now! Look at the various avenues the drugs can be adopted in! Good luck to genuine holders. I'm convinced as I mentioned before PH are trying to play the share price before imminent fantastic update. They are a despicable company. Its very interesting the timing of the trolls appearing. |
Posted at 04/6/2024 14:39 by peaceandlove A recap me thinks.1)MHRA refused Sareum a clinical trial. One can only imagine why. I suspect they felt the novel formulation is not a sufficient innovation to expose fit and healthy volunteer-patients to the risks of the trial. 2) The Clinical Trial is a phase 1 protocol. This assesses only the basic safety of the new molecule and has nothing to do with whether it will work or not. It can be compared with base camp for the climb to the summit of Everest. 3)The company admits that to go forward through and beyond the Phase 1 trial, it will have to go back to investors to raise more money. This is not good and could result in a dilution of your share holding or a share price reduction. I leave it to your imagination as to the struggle Sareum will have if the Phase 1 outcome is unfavourable. 4) No revenue 5) No license deals 6) share price down 68% since this time last year despite Sareum having their first clinical trial after 20 years. All facts! Not so cool Boo 👻 Hoo needs to stay of the special brew. PMSL |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
